The scarcity of essential medical treatment for individuals with cystic fibrosis is compelling families to seek care abroad. In Kosovo, the specialized therapy required for managing cystic fibrosis is reportedly unavailable, prompting continuous advocacy from medical professionals and parents. For years, local advocates have petitioned for the inclusion of the medication Trikafta on the national Essential Medicines List.
Despite these persistent requests, the drug remains inaccessible within the country. According to parents of affected children, obtaining the medication necessitates travel to other nations, where the minimum monthly cost has been reported to reach 15,000 euros. Advocates point to international reports detailing the efficacy of this specific therapy, noting that for many patients in developed countries, the drug has demonstrated significant positive impacts on overall health outcomes.
This gap between necessary care and local availability presents a substantial hurdle for families. The inability to access this critical treatment locally means that families managing cystic fibrosis must undertake complex and costly migrations to secure necessary medical intervention. The situation highlights a significant disparity in healthcare resources for patients suffering from this chronic condition.
The ongoing need underscores the urgency for policy changes to ensure that life-sustaining therapy for cystic fibrosis is accessible within the region.
Topics: #cystic #fibrosis #therapy
